Purpose of this Study
The purpose of this study is to find out if combining a bispecific antibody with a drug called selinexor (XPOVIO) is a safe and effective option for multiple myeloma patients whose disease has returned after treatment or did not adequately respond to treatment.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with multiple myeloma
- Have disease that returned after treatment or did not respond to treatment
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you choose take part in this study, you will receive the study drug selinexor, along with bispecific antibodies that you would already be taking, for 12 months. Selinexor (XPOVIO) is approved by the U.S. Food and Drug Administration (FDA) for use in certain patients with RRMM, who have received at least 4 prior medications and whose disease is no longer responding to certain types of medication. As part of this study, you will have tests, exams, and procedures done as part of your normal care and for research.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
A phase II safety and efficacy study of Selinexor in combination with bispecific antibody in patients with relapsed/refractory multiple myeloma
Principal Investigator
Yubin
Kang
Protocol Number
PRO00115964
NCT ID
NCT06822972
Phase
II
Enrollment Status
Pending Open to Enrollment